Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

Some blind vision loss cases have been linked to the use of weight-loss jabs, including Ozempic, so caution is recommended by ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...